BNP Paribas Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$207M Buy
331,560
+58,440
+21% +$39.8M 0.21% 91
2026
Q1
$211M Buy
273,120
+26,644
+11% +$20.4M 0.24% 78
2025
Q4
$190M Buy
246,476
+11,644
+5% +$7.91M 0.22% 86
2025
Q3
$132M Sell
234,832
-205,592
-47% -$116M 0.34% 57
2025
Q2
$231M Sell
440,424
-91,790
-17% -$51.2M 0.56% 29
2025
Q1
$338M Buy
532,214
+20,658
+4% +$14.2M 0.91% 16
2024
Q4
$364M Buy
511,556
+25,709
+5% +$21.6M 0.9% 15
2024
Q3
$511M Sell
485,847
-14,427
-3% -$16.1M 1.27% 9
2024
Q2
$526M Buy
500,274
+96,266
+24% +$93.3M 1.36% 9
2024
Q1
$389M Buy
404,008
+18,788
+5% +$17.9M 1.03% 11
2023
Q4
$338M Buy
385,220
+202,735
+111% +$167M 0.94% 15
2023
Q3
$150M Buy
182,485
+66,664
+58% +$52.4M 0.46% 43
2023
Q2
$83.2M Buy
115,821
+43,259
+60% +$33.4M 0.26% 96
2023
Q1
$59.6M Buy
72,562
+3,218
+5% +$2.43M 0.21% 119
2022
Q4
$50M Sell
69,344
-690
-1% -$509K 0.18% 143
2022
Q3
$48.2M Buy
70,034
+43,926
+168% +$27.6M 0.19% 125
2022
Q2
$15.4M Buy
26,108
+2,156
+9% +$1.4M 0.06% 321
2022
Q1
$16.7M Buy
23,952
+7,200
+43% +$4.56M 0.06% 328
2021
Q4
$10.6M Buy
16,752
+9,281
+124% +$5.71M 0.04% 435
2021
Q3
$4.52M Buy
7,471
+400
+6% +$248K 0.02% 565
2021
Q2
$3.95M Sell
7,071
-1,453
-17% -$736K 0.01% 589
2021
Q1
$4.03M Sell
8,524
-414
-5% -$202K 0.02% 559
2020
Q4
$4.32M Buy
8,938
+50
+0.6% +$27K 0.02% 524
2020
Q3
$4.97M Buy
8,888
+4,528
+104% +$2.75M 0.03% 435
2020
Q2
$2.72M Sell
4,360
-1,196
-22% -$679K 0.02% 528
2020
Q1
$2.71M Buy
5,556
+2,357
+74% +$972K 0.02% 508
2019
Q4
$1.2M Sell
3,199
-1,386
-30% -$466K 0.01% 638
2019
Q3
$1.27M Sell
4,585
-1,299
-22% -$384K 0.01% 646
2019
Q2
$1.84M Buy
5,884
+3,895
+196% +$1.3M 0.02% 575
2019
Q1
$817K Sell
1,989
-154
-7% -$63.4K 0.01% 728
2018
Q4
$777K Buy
2,143
+197
+10% +$72.1K 0.01% 737
2018
Q3
$786K Buy
1,946
+122
+7% +$46.4K 0.01% 738
2018
Q2
$629K Hold
1,824
0.01% 798
2018
Q1
$628K Buy
1,824
+260
+17% +$90.4K 0.01% 795
2017
Q4
$588K Sell
1,564
-137
-8% -$55.5K 0.01% 798
2017
Q3
$761K Sell
1,701
-432
-20% -$206K 0.01% 774
2017
Q2
$1.05M Sell
2,133
-588
-22% -$257K 0.01% 741
2017
Q1
$1.05M Sell
2,721
-790
-23% -$293K 0.01% 752
2016
Q4
$1.29M Sell
3,511
-4,622
-57% -$1.76M 0.01% 730
2016
Q3
$3.27M Sell
8,133
-271
-3% -$109K 0.03% 608
2016
Q2
$2.94M Buy
8,404
+404
+5% +$156K 0.02% 612
2016
Q1
$2.88M Buy
8,000
+176
+2% +$72.5K 0.02% 599
2015
Q4
$4.25M Buy
7,824
+1
+0% +$542 0.04% 505
2015
Q3
$3.64M Sell
7,823
-424
-5% -$228K 0.03% 543
2015
Q2
$4.21M Sell
8,247
-2,774
-25% -$1.35M 0.03% 541
2015
Q1
$4.98M Buy
11,021
+3,577
+48% +$1.52M 0.04% 487
2014
Q4
$3.05M Buy
7,444
+2,680
+56% +$1.05M 0.02% 535
2014
Q3
$1.72M Sell
4,764
-159
-3% -$53.3K 0.01% 645
2014
Q2
$1.39M Sell
4,923
-3,964
-45% -$1.17M 0.01% 718
2014
Q1
$2.67M Buy
8,887
+4,041
+83% +$1.24M 0.02% 578
2013
Q4
$1.33M Buy
4,846
+4,112
+560% +$1.18M 0.01% 695
2013
Q3
$230K Buy
+734
New +$193K ﹤0.01% 786

Other funds holding REGN

BNP Paribas Asset Management's REGN Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 21% in Q2 2026, buying an estimated $39.8M and bringing the position to 331,560 shares worth $207M. The position accounts for 0.21% of the portfolio, ranked #91.

BNP Paribas Asset Management first reported a position in REGN in Q3 2013 and has held it in 52 quarters since. The position peaked at $526M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • BNP Paribas Asset Management held 331,560 shares of Regeneron Pharmaceuticals worth $207M as of Q2 2026.
  • BNP Paribas Asset Management bought 58,440 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $39.8M.
  • Regeneron Pharmaceuticals made up 0.21% of BNP Paribas Asset Management's portfolio in Q2 2026, its #91 holding.
  • BNP Paribas Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 52 quarters since.
  • BNP Paribas Asset Management's Regeneron Pharmaceuticals position peaked at $526M in Q2 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.